Evidence for the presence of L-arginine-nitric oxide pathway in human red blood cells: relevance in the effects of red blood cells on platelet function.

There is a renewed interest in the role of red blood cells (RBCs) in the regulation of vascular tone and platelet homeostasis. To examine whether human RBCs synthesize NO from L-arginine, which may mediate the antiplatelet effects of these cells, purified RBCs (10(7)-10(8)/ml) were incubated with [3H]L-arginine, and its conversion into [3H]L-citrulline determined. RBCs consistently converted [3H]L-arginine to [3H]L-citrulline in a Ca2+-dependent fashion, and this conversion was inhibited by two different specific NO synthase inhibitors. Suspension of RBCs (10(7)-10(8)/ml) reduced platelet aggregation, and the RBC-mediated inhibition of platelet aggregation was blocked by pretreatment of RBCs with NO synthase inhibitor and potentiated by pretreatment with superoxide dismutase. Release of serotonin by aggregating platelets also was inhibited in the presence of RBCs. Western analysis with a specific mouse monoclonal antibody provided direct evidence for the presence of human endothelium-type constitutive NO synthase with a molecular mass approximately 140 kDa in the RBC cytosol. These observations suggest that RBCs possess endothelium-type NO synthase and may regulate platelet function at least in part by in situ release of NO.

[1]  J. Mehta,et al.  Cardioprotective Effects of Red Blood Cells on Ischemia and Reperfusion Injury in Isolated Rat Heart: Release of Nitric Oxide as a Potential Mechanism , 1996, Journal of cardiovascular pharmacology and therapeutics.

[2]  J. Mehta,et al.  Oxidized LDL decreases L-arginine uptake and nitric oxide synthase protein expression in human platelets: relevance of the effect of oxidized LDL on platelet function. , 1996, Circulation.

[3]  K. Voss,et al.  Dominance of mineral dust in aerosol light-scattering in the North Atlantic trade winds , 1996, Nature.

[4]  J. Stamler,et al.  S-nitrosohaemoglobin: a dynamic activity of blood involved in vascular control , 1996, Nature.

[5]  J. Mehta,et al.  Protective Effect of Elastase Inhibition Against Myocardial Dysfunction and Injury Induced by Ischemia and Reperfusion in Isolated Rat Hearts , 1996, Journal of cardiovascular pharmacology and therapeutics.

[6]  J. Mehta,et al.  Identification of constitutive and inducible forms of nitric oxide synthase in human platelets. , 1995, The Journal of laboratory and clinical medicine.

[7]  J. Lancaster,et al.  Simulation of the diffusion and reaction of endogenously produced nitric oxide. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[8]  J. Mehta,et al.  Co-purification of 130 kD nitric oxide synthase and a 22 kD link protein from human neutrophils. , 1992, Biochemical and biophysical research communications.

[9]  J. Stamler,et al.  Nitric oxide circulates in mammalian plasma primarily as an S-nitroso adduct of serum albumin. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[10]  J. Lüthje,et al.  Demonstration of a novel ecto-enzyme on human erythrocytes, capable of degrading ADP and of inhibiting ADP-induced platelet aggregation. , 1988, European journal of biochemistry.

[11]  S. Moncada,et al.  L-arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation. , 1988, Biochemical and biophysical research communications.

[12]  S. Moncada,et al.  Vascular endothelial cells synthesize nitric oxide from L-arginine , 1988, Nature.

[13]  P. Noris,et al.  The effect of red cells on platelet aggregation: a study with the electronic whole blood aggregometer. , 1988, Scandinavian journal of clinical and laboratory investigation.

[14]  R. Parks,et al.  Potentiation of the antiplatelet action of adenosine in whole blood by dipyridamole or dilazep and the cAMP phosphodiesterase inhibitor, RA 233. , 1986, Thrombosis research.

[15]  L. Pataki,et al.  Comparison of antioxidant red blood cell enzymes in premature and full-term neonates. , 1985, Clinica chimica acta; international journal of clinical chemistry.

[16]  L. Ignarro,et al.  Evidence for the inhibitory role of guanosine 3', 5'-monophosphate in ADP-induced human platelet aggregation in the presence of nitric oxide and related vasodilators. , 1981, Blood.

[17]  E. Jellum,et al.  The presence of furan derivatives in patients receiving fructose-containing solutions intravenously. , 1973, Clinica chimica acta; international journal of clinical chemistry.

[18]  J. Mehta,et al.  Variable effects of L-arginine analogs on L-arginine-nitric oxide pathway in human neutrophils and platelets may relate to different nitric oxide synthase isoforms. , 1996, The Journal of pharmacology and experimental therapeutics.

[19]  H. Schmidt,et al.  Is arginine a physiological precursor of endothelium-derived nitric oxide? , 1988, European journal of pharmacology.